XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity
 9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Stockholders' Equity

4. STOCKHOLDERS' EQUITY

Following the closing of the Company's IPO, the Company's authorized capital stock consists of 200,000,000 shares of common stock, with a par value of $0.0001 per share, and 50,000,000 shares of preferred stock, with a par value of $0.0001 per share, all of which preferred stock are undesignated.

See Note 2 for a summary of the Reorganization and Liquidation of Rallybio Holdings that was completed prior to the Company's IPO, which resulted in a change in reporting entity. In accordance with the applicable accounting guidance related to changes in reporting entities, the financial statements for all periods presented have been retrospectively adjusted giving effect to the Reorganization and Liquidation as applicable to all periods presented. All preferred unit financing activity prior to the completion of the Company's IPO has been retrospectively adjusted in these financial statements to reflect the shares in Rallybio Corporation that were obtained in the Liquidation. For additional information on preferred unit financing prior to the Company's IPO and the Liquidation of Rallybio Holdings see the Company's audited consolidated financial statements for the year ended December 31, 2020 and notes thereto contained in the Company’s IPO Prospectus.

During the nine months ended September 30, 2020, the Company entered into a Series B Preferred Stock Agreement with a total aggregate purchase price of $145.2 million which has been retrospectively adjusted to reflect the shares of common stock obtained during the Reorganization and Liquidation of Rallybio Holdings, see Note 2.